Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation

Stock Information for Ur-Energy Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ur-Energy Inc.

Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.